全球小分子CDMO市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

小分子量 CDMO 市場預計將從 2025 年的 825.8 億美元成長到 2034 年的 1,578 億美元，2026 年至 2034 年的複合年成長率為 7.46%。

隨著製藥公司持續將藥物研發和生產外包，全球小分子藥物合約研發生產力機構（CDMO）市場正經歷強勁成長。小分子藥物因其穩定性好、易於口服且成本效益高，仍被廣泛使用。不斷成長的在研藥物和專利到期正在推動製藥公司與CDMO建立合作關係，以實現高效生產。

關鍵成長要素包括對學名藥需求的不斷成長以及製程最佳化技術的進步。癌症和慢性病治療領域研究的拓展也推動了成長。合約研發生產機構（CDMO）憑藉其擴充性、監管專業知識和成本優勢，成為製藥公司不可或缺的合作夥伴。

未來前景光明，主要得益於連續生產和先進分析技術的日益普及。隨著新興市場的拓展和臨床試驗活動的增加，對專業小分子藥物生產服務的需求預計將進一步成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球低分子量CDMO市場：依產品分類

• 市場分析、洞察與預測
• 藥物原料藥（API）
• 已完成的藥品

第5章：全球小分子CDMO市場：依藥物類型分類

• 市場分析、洞察與預測
• 創新者
• 學名藥

第6章：全球低分子量CDMO市場：依應用分類

• 市場分析、洞察與預測
• 腫瘤學
• 心血管疾病
• 中樞神經系統疾病
• 自體免疫疾病/炎症
• 其他

第7章 全球低分子量CDMO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza
  • Catalent Inc
  • Thermo Fisher Scientific Inc
  • Cambrex Corporation
  • Bellen Chemistry
  • Siegfried Holding AG
  • Recipharm AB
  • Eurofins Scientific
  • Aurigene Pharmaceutical Services Ltd
  • CordenPharma International

The Small Molecule CDMO Market size is expected to reach USD 157.80 Billion in 2034 from USD 82.58 Billion (2025) growing at a CAGR of 7.46% during 2026-2034.

The global small molecule CDMO market is experiencing strong growth as pharmaceutical companies continue to outsource drug development and manufacturing. Small molecule drugs remain widely used due to their stability, oral availability, and cost-effectiveness. Increasing drug pipelines and patent expirations are encouraging partnerships with CDMOs for efficient production.

Major drivers include rising demand for generic drugs and advancements in process optimization technologies. Expanding research in oncology and chronic disease therapies also supports growth. CDMOs offer scalability, regulatory expertise, and cost advantages, making them essential partners for pharmaceutical companies.

Future prospects are promising with increased adoption of continuous manufacturing and advanced analytical technologies. Expansion into emerging markets and growing clinical trial activity are expected to further boost demand for specialized small molecule manufacturing services.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Active Pharmaceutical Ingredients (API)
• Finished Drug Products

By Drug Type

• Innovators
• Generics

By Application

• Oncology
• Cardiovascular Disease
• Central Nervous System (CNS) Conditions
• Autoimmune/Inflammation
• Others

COMPANIES PROFILED

• Lonza, Catalent Inc, Thermo Fisher Scientific Inc, Cambrex Corporation, Bellen Chemistry, Siegfried Holding AG, Recipharm AB, Eurofins Scientific, Aurigene Pharmaceutical Services Ltd, CordenPharma International
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SMALL MOLECULE CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Active Pharmaceutical Ingredients (API) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Finished Drug Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SMALL MOLECULE CDMO MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Innovators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SMALL MOLECULE CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Central Nervous System (CNS) Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Autoimmune/Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SMALL MOLECULE CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Drug Type
  • 7.2.3 By Application
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Drug Type
  • 7.3.3 By Application
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Drug Type
  • 7.4.3 By Application
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Drug Type
  • 7.5.3 By Application
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Drug Type
  • 7.6.3 By Application
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SMALL MOLECULE CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza
  • 9.2.2 Catalent Inc
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Cambrex Corporation
  • 9.2.5 Bellen Chemistry
  • 9.2.6 Siegfried Holding AG
  • 9.2.7 Recipharm AB
  • 9.2.8 Eurofins Scientific
  • 9.2.9 Aurigene Pharmaceutical Services Ltd
  • 9.2.10 CordenPharma International